Cell line · CVCL_1728
Papers39
1 to 20 of 39
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| KDM6A loss enhances oxidative phosphorylation uncovering tissue-level convergent evolution. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-based gene expression platform for precise regulation of bladder cancer. | Cell Mol Biol Lett | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression. | Cell Biosci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| p53 mitigates the effects of oncogenic HRAS in urothelial cells via the repression of MCOLN1. | iScience | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. | Nat Commun | 2019 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines. | Bladder Cancer | 2018 | Cellosaurus cites it | PubMed | |
| Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. | Oncogene | 2017 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1728/papers